Full video transcriptClick to expand
Auto-generated transcript of @markusfit's video. Quoted here for educational fact-check commentary; original creator retains all rights to the video content.
- 0:00How many iUs of 8cg do i use on a cruise? Here's my cruising physique around 225 pounds. I broke
- 0:06this down so you guys knew exactly how i was doing mine so on a 12,000 iU vial of 8cg
- 0:10reconstitute with 6 milliliters of backwater equals 2,000 iUs per ml or cc. And of that 2,000
- 0:17iUs in one ml, I'm going to be injecting a quarter or 0.25 ml into meat twice a week which equals 500
- 0:25units. So i'm doing 500 units twice a week which is 1,000 iUs total. Now on a slim pin that would be
- 0:31to the 25 okay both of these are slim pins the only difference is one holds more volume than the
- 0:35other okay but on this slim pin the 25 is right here and on this slim pin the 25 is right here.
- 0:40I know this sounds so stupid to a lot of people but you guys would be surprised. For those wondering
- 0:44where i get my 8cg i get it from transcend hrt the link is in the box guys are interested i like
- 0:49it because you get your vials it tells you exactly how to run it and everything you need to do.
- 0:52If you have any questions or if you ever run into any problems there's a wellness specialist
- 0:55that's more than happy to help you through the entire process but anyways on your cruise 8 to 12
- 0:59weeks of this protocol and then blast off again.
HCG and TRT: what the 'pullout game' joke reveals about fertility risks
Quick answer
The creator describes a self-administered HCG protocol of 1,000 IU per week (500 IU twice weekly, IM) during a testosterone cruise phase, sourced from a telehealth provider. While HCG is clinically used during TRT to preserve testicular volume and fertility potential, evidence supports lower doses (250-500 IU twice weekly subcutaneously) as equally effective with a lower risk of estradiol elevation and Leydig cell desensitization. No mention is made of estradiol monitoring, which is a standard clinical consideration when adding HCG to a testosterone protocol.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 3 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For HCG and TRT: what the 'pullout game' joke reveals about fertility risks, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Cardiovascular Safety of Testosterone-Replacement Therapy
TRAVERSE trial anchor for cardiovascular-safety discussions in appropriately diagnosed men.
PubMed
Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline
Guideline anchor for diagnosis, monitoring, contraindications, and appropriate TRT framing.
PubMed
Provider decision path
Use local research to choose a safer review path
Direct answer
HCG and TRT: what the 'pullout game' joke reveals about fertility risks is best used to compare access, oversight, pricing, pharmacy quality, and patient support before starting care.
Evidence check
Directory pages should connect local intent with provider standards, pharmacy transparency, and practical next steps.
Safety check
Provider quality, pharmacy source, prescribing model, and follow-up support can matter as much as the medication name.
Next step
When you are ready, the get-started flow can collect the details needed for a prescription review instead of leaving you to guess.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Page-specific review note
What this exact clip is really saying
This FormBlends review is specific to "HCG and TRT: what the 'pullout game' joke reveals about fertility risks" from Markusfit. We read the clip as a TRT social video fact-checks claim about Testosterone, then separate the useful signal from what a short social video cannot prove. The page-specific claim focus is: The creator describes a self-administered HCG protocol of 1,000 IU per week (500 IU twice weekly, IM) during a testosterone cruise phase, sourced from a telehealth provider.
The reason this review is not generic is the source wording and the canonical claim label "trt replying to thanos pullout game better be strong when in hcg." In this clip, the useful excerpt is: "How many iUs of 8cg do i use on a cruise?" That wording changes the review because it points to Testosterone evidence, safety, and patient-fit context, not a one-size-fits-all protocol.
The source trail for this page is checked against Cardiovascular Safety of Testosterone-Replacement Therapy (2023), Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline (2010), and Functional testosterone deficiency in aging men: Clinical impact, diagnostic pathways, and treatment strategies (2026), plus the creator's own wording. Testosterone decisions still need an eligibility review, medication-interaction screen, access check, and quality-control review before anyone treats a social clip as medical advice.
Claim verdict
The useful answer behind this video
This page is built to answer the specific claim behind the clip, then separate what is useful from what still needs clinical context. That makes the URL more than a repost: it gives Google, readers, and AI retrieval systems a concise verdict with source and safety boundaries.
Claim being checked
The creator describes a self-administered HCG protocol of 1,000 IU per week (500 IU twice weekly, IM) during a testosterone cruise phase, sourced from a telehealth provider.
FormBlends verdict
Testosterone evidence, safety, and patient-fit context
Evidence strength
Source-backed review with clinical or regulatory citations.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The creator describes a self-administered HCG protocol of 1,000 IU per week (500 IU twice weekly, IM) during a testosterone cruise phase, sourced from a telehealth provider. While HCG is clinically used during TRT to preserve testicular volume and fertility potential, evidence supports lower doses (250-500 IU twice weekly subcutaneously) as equally effective with a lower risk of estradiol elevation and Leydig cell desensitization. No mention is made of estradiol monitoring, which is a standard clinical consideration when adding HCG to a testosterone protocol.
- Coviello et al. (2005, JCEM) found that approximately 437 IU/week of HCG was sufficient to maintain intratesticular testosterone in men on exogenous testosterone, well below the 1,000 IU/week this video recommends.
- Liu et al. (2009, JCEM) documented Leydig cell LH-receptor desensitization with high-frequency, higher-dose HCG use, meaning more HCG can actually reduce testicular responsiveness over time.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Coviello et al. (2005, JCEM) found that approximately 437 IU/week of HCG was sufficient to maintain intratesticular testosterone in men on exogenous testosterone, well below the 1,000 IU/week this video recommends.
- Liu et al. (2009, JCEM) documented Leydig cell LH-receptor desensitization with high-frequency, higher-dose HCG use, meaning more HCG can actually reduce testicular responsiveness over time.
- Subcutaneous injection is the standard clinical delivery route for HCG, not intramuscular. Both work, but subQ is associated with less discomfort and is the protocol used in most peer-reviewed studies.
- HCG stimulates estradiol production alongside testosterone. Any HCG protocol should include estradiol monitoring, a consideration completely absent from this video.
- Wenker et al. (2013, Journal of Urology) confirmed lower-dose HCG protocols preserved fertility markers during TRT, supporting the view that higher doses offer diminishing returns.
- The reconstitution math and syringe marking explanation in this video are accurate and represent genuinely useful harm-reduction information for people already prescribed HCG.
- A self-administered protocol shared on TikTok is not a substitute for a licensed provider who can assess your individual hormone panel before and during HCG use.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team · This is not a transcript. It is our independent review of the video above.
What did @markusfit actually say?
Markus laid out a specific HCG protocol for his TRT cruise phase: reconstituting a 12,000 IU vial with 6 mL of bacteriostatic water to get 2,000 IU/mL, then injecting 0.25 mL (500 IU) twice weekly into muscle for a total of 1,000 IU per week. He also clarified syringe markings for slim pins, said he runs this for "8 to 12 weeks" before blasting again, and disclosed he sources his HCG from Transcend HRT.
That's actually more math transparency than most TRT content creators bother with. He walked through unit conversion, syringe volume, and injection frequency in plain language. That part deserves credit. The problems, though, are in the details.
Does the science back this up?
Partially. HCG at lower doses during a testosterone cruise is a real, studied practice, primarily for preserving testicular function and endogenous LH-axis activity. But 1,000 IU per week is on the higher end of what the literature supports for that goal.
A 2005 study by Coviello et al. in the Journal of Clinical Endocrinology and Metabolism found that 125 IU every other day (roughly 437 IU/week) was sufficient to maintain intratesticular testosterone in men on exogenous testosterone. A 2013 analysis by Wenker et al. in the Journal of Urology confirmed that lower-dose HCG protocols were effective for preserving fertility markers during TRT. Neither study found meaningful added benefit from doses above 500 IU every other day. At 1,000 IU/week, you're likely not getting more benefit, but you may be getting more estradiol conversion and more desensitization of Leydig cell LH receptors over time.
What did they get wrong (or right)?
The math is right. The reconstitution logic, the unit conversion, the syringe markings explanation, all accurate. That's genuinely useful harm-reduction content for people who are already using HCG and fumbling with vials.
What's questionable is the dose framing. Calling 1,000 IU/week a standard cruise protocol without noting that research supports much lower doses is misleading by omission. Injecting HCG "into meat" (intramuscularly) is also worth flagging. HCG is typically administered subcutaneously in clinical protocols. A 2017 review in Fertility and Sterility by Boehm et al. noted subcutaneous delivery produces comparable bioavailability with less discomfort. IM injection isn't dangerous, but it's not the evidence-based default either.
The 8-to-12-week cruise framing is also presented without any context about what the "blast" involves, which matters a great deal for risk assessment.
What should you actually know?
HCG during a testosterone cruise is used to keep the testes producing some testosterone and to preserve fertility potential. That's a legitimate clinical goal. But the dose matters, and more is not better here.
Chronic supraphysiologic HCG use can desensitize LH receptors on Leydig cells, which is the opposite of what most users want long-term. A 2009 study by Liu et al. in the Journal of Clinical Endocrinology and Metabolism documented Leydig cell desensitization with high-frequency HCG dosing. Most clinical providers managing TRT with HCG now use 250 to 500 IU twice weekly at most, not 1,000 IU/week as a floor.
The syringe tutorial is genuinely helpful for people already prescribed HCG who are confused about unit markings. But this video presents one person's self-administered protocol as a template, without a prescriber in the frame. If you're considering HCG as part of a TRT protocol, that conversation needs to happen with a licensed provider who can check your LH, FSH, and estradiol, not from a TikTok reconstitution demo.
Bottom line on the claims
The technical content here is better than average for TRT social media. The math is solid, the syringe explanation is clear, and at least he disclosed his source. But 1,000 IU/week sits above what the peer-reviewed evidence supports for cruise-phase HCG, the IM injection route isn't standard, and there's zero mention of monitoring estradiol, which rises predictably with HCG use. Those are real gaps.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
Markusfit · TikTok creator
57.1K views on this video
Replying to @Thanos pullout game better be strong when in HCG
Frequently asked questions
Quick answers based on this video and our medical team review.
What does the video say about coviello et al. (2005, jcem) found?
Coviello et al. (2005, JCEM) found that approximately 437 IU/week of HCG was sufficient to maintain intratesticular testosterone in men on exogenous testosterone, well below the 1,000 IU/week this video recommends.
What does the video say about liu et al. (2009, jcem) documented leydig cell lh-receptor desensitization?
Liu et al. (2009, JCEM) documented Leydig cell LH-receptor desensitization with high-frequency, higher-dose HCG use, meaning more HCG can actually reduce testicular responsiveness over time.
What does the video say about subcutaneous injection?
Subcutaneous injection is the standard clinical delivery route for HCG, not intramuscular. Both work, but subQ is associated with less discomfort and is the protocol used in most peer-reviewed studies.
What does the video say about hcg stimulates estradiol production alongside testosterone. any hcg protocol should?
HCG stimulates estradiol production alongside testosterone. Any HCG protocol should include estradiol monitoring, a consideration completely absent from this video.
What does the video say about wenker et al. (2013, journal of urology) confirmed lower-dose hcg?
Wenker et al. (2013, Journal of Urology) confirmed lower-dose HCG protocols preserved fertility markers during TRT, supporting the view that higher doses offer diminishing returns.
What does the video say about the reconstitution math?
The reconstitution math and syringe marking explanation in this video are accurate and represent genuinely useful harm-reduction information for people already prescribed HCG.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by Markusfit, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.